T. Rowe Price Associates
ALLO icon

T. Rowe Price Associates’s Allogene Therapeutics ALLO Stock Holding History

T. Rowe Price Associates’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.1M Buy
5,380,902
+2,171,627
+68% +$4.35M ﹤0.01% 1149
2025
Q4 		$4.4M Sell
3,209,275
-468,199
-13% -$618K ﹤0.01% 1430
2025
Q3 		$4.56M Sell
3,677,474
-353,398
-9% -$421K ﹤0.01% 1419
2025
Q2 		$4.56M Sell
4,030,872
-175,132
-4% -$233K ﹤0.01% 1299
2025
Q1 		$6.14M Sell
4,206,004
-279,568
-6% -$527K ﹤0.01% 1213
2024
Q4 		$9.55M Sell
4,485,572
-353,171
-7% -$871K ﹤0.01% 1166
2024
Q3 		$13.6M Sell
4,838,743
-951,799
-16% -$2.54M ﹤0.01% 1082
2024
Q2 		$13.5M Buy
5,790,542
+1,612,923
+39% +$4.76M ﹤0.01% 1052
2024
Q1 		$18.7M Buy
4,177,619
+1,806,147
+76% +$7.54M ﹤0.01% 989
2023
Q4 		$7.61M Sell
2,371,472
-35,875
-1% -$102K ﹤0.01% 1145
2023
Q3 		$7.63M Sell
2,407,347
-2,924,053
-55% -$12.8M ﹤0.01% 1110
2023
Q2 		$26.5M Sell
5,331,400
-998,904
-16% -$5.4M ﹤0.01% 860
2023
Q1 		$31.3M Buy
6,330,304
+388,507
+7% +$2.49M ﹤0.01% 810
2022
Q4 		$37.4M Buy
5,941,797
+34,481
+0.6% +$319K 0.01% 740
2022
Q3 		$63.8M Buy
5,907,316
+348,140
+6% +$4.73M 0.01% 586
2022
Q2 		$63.4M Buy
5,559,176
+1,292,441
+30% +$11.5M 0.01% 805
2022
Q1 		$38.9M Buy
4,266,735
+1,015,207
+31% +$10.6M ﹤0.01% 1055
2021
Q4 		$48.5M Sell
3,251,528
-1,087,463
-25% -$19.2M ﹤0.01% 1017
2021
Q3 		$112M Buy
4,338,991
+803,807
+23% +$19.1M 0.01% 731
2021
Q2 		$92.2M Buy
3,535,184
+78,431
+2% +$2.24M 0.01% 808
2021
Q1 		$122M Sell
3,456,753
-103,040
-3% -$3.48M 0.01% 711
2020
Q4 		$89.8M Sell
3,559,793
-17,891
-0.5% -$583K 0.01% 756
2020
Q3 		$135M Sell
3,577,684
-213,102
-6% -$8.03M 0.02% 582
2020
Q2 		$162M Buy
3,790,786
+1,586,252
+72% +$57.4M 0.02% 516
2020
Q1 		$42.9M Sell
2,204,534
-265,976
-11% -$6.34M 0.01% 831
2019
Q4 		$64.2M Sell
2,470,510
-48,162
-2% -$1.33M 0.01% 817
2019
Q3 		$68.6M Sell
2,518,672
-4,234
-0.2% -$121K 0.01% 746
2019
Q2 		$67.7M Buy
2,522,906
+3,398
+0.1% +$94.7K 0.01% 770
2019
Q1 		$70.9M Buy
2,519,508
+7,510
+0.3% +$218K 0.01% 738
2018
Q4 		$65.9M Buy
+2,511,998
New +$66.7M 0.01% 722

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

T. Rowe Price Associates's ALLO Position: Q1 2026 in Review

T. Rowe Price Associates increased its Allogene Therapeutics (ALLO) stake by 68% in Q1 2026, buying an estimated $4.35M and bringing the position to 5,380,902 shares worth $13.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1149.

T. Rowe Price Associates first reported a position in ALLO in Q4 2018 and has held it in 30 quarters since. The position peaked at $162M in Q2 2020. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • T. Rowe Price Associates held 5,380,902 shares of Allogene Therapeutics worth $13.1M as of Q1 2026.
  • T. Rowe Price Associates bought 2,171,627 Allogene Therapeutics shares in Q1 2026, an estimated $4.35M.
  • Allogene Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1149 holding.
  • T. Rowe Price Associates first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 30 quarters since.
  • T. Rowe Price Associates's Allogene Therapeutics position peaked at $162M in Q2 2020.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.